Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-patient M201-A hydrochloride in Japanese paroxysmal atrial fibrillation
jRCT2031190069Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of m201-a in Atrial fibrillation (AFib) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety assessment and Arrest of atrial fibrillation within 2 hours. Started Oct 2019; status: recruiting.
02
Drugs
m201-a
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2031190069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190069.